
## Omar F Abouezzeddine

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8739540/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	99mTechnetium-pyrophosphate cardiac scintigraphy cases from a busy nuclear cardiology laboratory. Journal of Nuclear Cardiology, 2022, 29, 2157-2167.	2.1	0
2	Rituximab for the Treatment of Refractory Cardiac Sarcoidosis: A Single-Center Experience. Journal of Cardiac Failure, 2022, 28, 247-258.	1.7	16
3	Cardiac sarcoidosis cases from a busy nuclear cardiology laboratory. Journal of Nuclear Cardiology, 2021, 28, 1553-1568.	2.1	0
4	Impact of Arrhythmias on Hospitalizations in Patients With Cardiac Amyloidosis. American Journal of Cardiology, 2021, 143, 125-130.	1.6	18
5	Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis on Frequency of Venous Thromboembolism. American Journal of Cardiology, 2021, 149, 112-118.	1.6	5
6	Sex-specific cut-off values for soluble suppression of tumorigenicity 2 (ST2) biomarker increase its cardiovascular prognostic value in the community. Biomarkers, 2021, 26, 639-646.	1.9	7
7	Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2021, 6, 1267.	6.1	66
8	Abstract 10726: Cardiac Resynchronization Therapy Response in Cardiac Sarcoidosis. Circulation, 2021, 144, .	1.6	0
9	Chloroquine and Hydroxychloroquine Myopathy: Clinical Spectrum and Treatment Outcomes. Frontiers in Neurology, 2020, 11, 616075.	2.4	12
10	Imaging cardiac sarcoidosis and infiltrative diseases: diagnosis and therapeutic response. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 51-73.	0.7	2
11	Myocardial Energetics in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e006240.	3.9	29
12	Transthyretin amyloidosis in Western Europe: a snapshot from the THAOS registry and a call for further perspectives. European Heart Journal, 2019, , .	2.2	3
13	Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis. Transplantation, 2018, 102, 1909-1913.	1.0	18
14	Clinical Significance of Early Fluid and Weight Change During Acute Heart Failure Hospitalization. Journal of Cardiac Failure, 2018, 24, 542-549.	1.7	13
15	Comparing Measures to Assess Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 552-560.	4.1	34
16	Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations. JACC: Heart Failure, 2016, 4, 923-931.	4.1	40
17	Timing and Causes of Readmission After Acute Heart Failure Hospitalization—Insights From the Heart Failure Network Trials. Journal of Cardiac Failure, 2016, 22, 875-883.	1.7	78
18	Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. Journal of Cardiac Failure, 2016, 22, 738-742.	1.7	23

#	Article	IF	CITATIONS
19	Evaluation of a provocative dyspnea severity score in acute heart failure. American Heart Journal, 2016, 172, 34-41.	2.7	9
20	Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. Journal of Cardiac Failure, 2016, 22, 884-890.	1.7	35
21	Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. Journal of Cardiac Failure, 2016, 22, 853-858.	1.7	7
22	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. Circulation: Heart Failure, 2015, 8, 741-748.	3.9	235
23	Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute HeartÂFailure. JACC: Heart Failure, 2015, 3, 97-107.	4.1	95
24	Galectin-3 in Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2015, 3, 245-252.	4.1	49
25	Targeting the Kidney in Acute Heart Failure: Can Old Drugs Provide New Benefit?. Circulation: Heart Failure, 2013, 6, 1087-1094.	3.9	27